FDA staff scrutinizes new hot-flash remedies

Staffers at the FDA weighed in new drugs from Depomed and Hisamitsu Pharmaceutical for combating post-menopausal hot flashes, saying that the drugs showed efficacy while raising no new red flags on safety, Reuters reported. Depomed shares spiked yesterday as the company races with Hisamitsu to garner the first FDA approvals of non-hormonal drugs for tempering hot flashes, even though Depomed's drug fell short of efficacy goals in trials. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.